Large-scale transcript variants dictate neoepitopes for cancer immunotherapy

Neoantigen tumor vaccines have shown promising anti-tumor efficacy in early clinical trials. However, the underlying mechanism regarding response or resistance to this treatment remains unclear. Therefore, further studies using advanced technologies such as single-cell RNA sequencing (scRNA-seq) were performed to reveal significant changes in tumor microenvironment after vaccination. Tumor-infiltrating immune cells of MC38 tumors were isolated by Fluorescence activated cell sorting (FACS) according to the presence or absence of CD45+ cells, and analyzed using scRNA-seq/TCR-seq.